Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab dose-ranging in rheumatoid arthritis
NCT01242488Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2010
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of olokizumab in rheumatoid arthritis (RA) (9 arms), sponsored by UCB. Primary endpoint: Disease Activity Score 28-joint count C-reactive protein at Week 12. Started Nov 2010; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01242488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242488.